BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 330 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2022. The put-call ratio across all filers is 0.46 and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $8,667,000 | +14.6% | 73,100 | +33.2% | 0.01% | +25.0% |
Q4 2021 | $7,562,000 | -30.3% | 54,874 | -29.8% | 0.00% | -33.3% |
Q3 2021 | $10,851,000 | +141.9% | 78,116 | +69.1% | 0.01% | +100.0% |
Q2 2021 | $4,485,000 | +264.0% | 46,203 | +156.2% | 0.00% | +200.0% |
Q1 2021 | $1,232,000 | -51.4% | 18,032 | -39.1% | 0.00% | -50.0% |
Q4 2020 | $2,536,000 | +46.4% | 29,591 | +11.1% | 0.00% | +100.0% |
Q3 2020 | $1,732,000 | -18.9% | 26,643 | -8.8% | 0.00% | -50.0% |
Q2 2020 | $2,135,000 | +320.3% | 29,205 | +95.8% | 0.00% | – |
Q1 2020 | $508,000 | -36.3% | 14,918 | +1.9% | 0.00% | -100.0% |
Q4 2019 | $797,000 | +139.3% | 14,634 | +83.5% | 0.00% | – |
Q3 2019 | $333,000 | -71.2% | 7,977 | -69.8% | 0.00% | -100.0% |
Q2 2019 | $1,155,000 | -3.5% | 26,379 | +13.4% | 0.00% | 0.0% |
Q1 2019 | $1,197,000 | +79.7% | 23,263 | +30.6% | 0.00% | 0.0% |
Q3 2017 | $666,000 | – | 17,817 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |